Nanovibronix, Inc. (NASDAQ:FEED – Get Free Report) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 161,665 shares, an increase of 165.7% from the June 30th total of 60,839 shares. Currently, 2.7% of the shares of the company are sold short. Based on an average daily volume of 507,400 shares, the days-to-cover ratio is presently 0.3 days.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a report on Tuesday, July 21st. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nanovibronix currently has a consensus rating of “Sell”.
View Our Latest Stock Report on Nanovibronix
Insider Activity
Nanovibronix Price Performance
FEED stock traded down $0.02 during trading on Tuesday, reaching $0.34. 87,213 shares of the stock were exchanged, compared to its average volume of 5,892,306. Nanovibronix has a twelve month low of $0.33 and a twelve month high of $17.40. The firm has a market capitalization of $2.05 million, a P/E ratio of -0.04 and a beta of 1.56. The business’s 50 day simple moving average is $0.67.
Nanovibronix (NASDAQ:FEED – Get Free Report) last posted its quarterly earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%. The firm had revenue of $0.65 million during the quarter.
About Nanovibronix
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.
See Also
- Five stocks we like better than Nanovibronix
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
- Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
- Is the Market Mispricing ServiceNow’s AI Future?
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
